TRACTION

Molecular pathogenesis of a novel thyroid hormone resistance syndrome caused by mutations in thyroid receptor alpha 1

Coordinatore	THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE    more  Organization address address: The Old Schools, Trinity Lane city: CAMBRIDGE postcode: CB2 1TN contact info Titolo: Ms. Nome: Renata Cognome: Schaeffer Email: send email Telefono: +44 1223 333543
Nazionalità Coordinatore	United Kingdom [UK]
Totale costo	115˙641 €
EC contributo	115˙641 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2012-IEF
Funding Scheme	MC-IEF
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-05-04   -   2014-05-03

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE  Organization address address: The Old Schools, Trinity Lane city: CAMBRIDGE postcode: CB2 1TN contact info Titolo: Ms. Nome: Renata Cognome: Schaeffer Email: send email Telefono: +44 1223 333543	UK (CAMBRIDGE)	coordinator	115˙641.60

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Thyroid hormone (TH) is crucial for the normal development and metabolism of all tissues. The actions of the bioactive T3 are mediated by binding to its nuclear receptors (TRs), of which TRa1 and TRb1 are the main isoforms. It is known for decades that mutations in TRb1 result in resistance to TH, among others characterized by goiter and tachycardia, and abnormal TH levels. Ever since its characterization in 1987, investigators have searched for patients with mutations in TRa1. However, very recently the host and applicant’s laboratory independently discovered the first patients with inactivating mutations in TRa1. These patients show growth retardation, delayed bone, motor and mental development as well as abnormal TH levels. The patients display remarkable differences in neurological, bone and biochemical phenotype. Interestingly, all mutants are located within exon 9, which encodes a domain important for ligand binding and interaction with co-activator and co-repressor proteins. It is likely that mutant-specific properties underlie the differences in clinical phenotype. The aim of this project is to unravel the molecular mechanisms leading to the clinical phenotype of patients with TRa1 mutations. The key objectives are: (i) to study direct effects of mutations in a reporter assay; (ii) to detail consequences of mutations on downstream target genes; (iii) to identify alterations in the interaction of the receptor mutants with cofactor proteins and (iv) to establish a genotype-phenotype relationship. Using an integrative approach with well-established and advanced techniques, this scientifically fascinating project will certainly deepen our understanding of the role of TRa1 in health and disease. The combination of the longstanding expertise of resistance to TH in the host laboratory together with my studies and experience concerning all aspects of cellular TH regulation will promise the success of this project.'